Sofosbuvir/Velpatasvir + Famotidine = Unknown or no reaction

Effect on Concentration

Sofosbuvir/Velpatasvir
No change
Applies within class?
No
Famotidine
Unknown
Applies within class?
No

Pharmacologic Effects

Sofosbuvir/Velpatasvir
Effect
N/A
Applies within class?
No
Famotidine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

Administration of SOF/VEL with histamine-2 receptor antagonists at doses comparable to FAM 40 mg given simultaneously or staggered resulted in no relevant changes in PK for SOF/VEL.

Sources

Sofosbuvir/velpatasvir vs rifampin, ethinylestradiol/norgestimate, or famotidine ^

Study Design

In a phase 1, multiple-dose, randomized, cross-over drug-drug interaction study with 24 healthy individuals, the pharmacokinetics (PK), safety, and tolerability of a once-daily regimen of sofosbuvir 400mg and velpatasvir 100mg (SOF/VEL) were evaluated when co-administered with rifampin 600mg twice-daily.

Study Results

Co-administration of FAM and SOF/VEL simultaneously resulted in no significant changes in the PK of SOF/VEL. When SOF/VEL was given 12 hours after FAM, only the Cmax of SOF decreased by 23%. The PK data for FAM was not reported.

Study Conclusions

References

E Mogalian, G Shen, L Moorehead, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination. Easl. Barcelona, Spain. ; 2016.